Aequus Pharmaceuticals Inc.
AQSZF
$0.00
$0.00-53.85%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 15.92% | -0.13% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.92% | -0.13% | |||
| Cost of Revenue | 8.63% | 27.39% | |||
| Gross Profit | 23.42% | -18.30% | |||
| SG&A Expenses | 10.76% | -7.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.95% | 2.38% | |||
| Operating Income | 4.07% | -8.85% | |||
| Income Before Tax | 327.00% | 73.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 327.00% | 73.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 327.00% | 73.64% | |||
| EBIT | 4.07% | -8.85% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 322.22% | 73.53% | |||
| Normalized Basic EPS | 16.67% | -20.00% | |||
| EPS Diluted | 322.22% | 73.53% | |||
| Normalized Diluted EPS | 16.67% | -20.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||